---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-009194"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:27:04.950769+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa gets 180-day NASDAQ extension to cure bid price deficiency

## Summary
- Received NASDAQ notice on Oct 5, 2022 for non-compliance with $1.00 minimum bid price rule.
- Deadline extended by 180 days to October 2, 2023, per company request.
- Company to monitor bid price and may consider reverse stock split if needed.
- No immediate effect on listing or trading of common stock.

## SEC filing metadata
- accession: 0001437749-23-009194
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923009194/0001437749-23-009194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923009194/atos20230403_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-009194
- JSON: https://secwatch.observer/filing/0001437749-23-009194.json
- Plain text: https://secwatch.observer/filing/0001437749-23-009194.txt

## Key facts
- Listing & Compliance Notices
  ATOSSA THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: April 4, 2023, the Company was informed that the deadline for compliance was extended by 180 days, or until October 2, 2023. The October 5, 2022 NASDAQ notice of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the NASDAQ Stock Market. The Company intends to actively monitor the bid price for its common stock between now and October 2, 2023, and will consider available options to resolve the deficiency and regain compliance with the minimum bid price requirement, including, if necessary, effectuating a reverse stock split. . * * * SIGNATURES Purs
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923009194/0001437749-23-009194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.